Breast Cancer Medications Pose Significant Health Threats

Those women that are on drugs such as raloxifene or tamoxifen could lower their chances of developing insidious breast cancer by nearly half, though in the due process might be at a higher risk of developing severe blood clots. This revealing piece of information was published in a novel paper that revaluates the threats and advantages of the drugs.

The scientists have stated that in every one thousand women that consume the medications every year, nearly seven to ten lesser reported breast cancer cases would surface.

However, both the medicines raise the likelihood of getting blood clots, with the maximum risk arising from tamoxifen medicine – in every one thousand women that consume tamoxifen every year, 4 to 10 more cases of blood clots crop up. This statistic was mentioned in the study that appeared during the current week in the ‘Annals of Internal Medicine’.

Tamoxifen is additionally known to raise the chances of developing endometrial cancer – a cancer that starts off in the endometrial lining of the uterus or womb that has a potential to be aggressive and spread to other areas of the body leading to a host of complications. Even cataract- a cloudy area that forms on the eye lens leading to an array of vision problems, is being cited as the associated risks for those women that take tamoxifen.

The third medicine, tibolone that has not garnered approval in the United States as yet, though it has been widely used in other parts of the world, was also included during the course of the study that was conducted. The paper cited that tibolone was known to majorly lower the risk of developing breast cancer, however raising the chances of stroke in elderly women.

Though, all the three drugs were reported to lower the likelihood of fractures. The paper gauges the threats and advantages of these drugs when employed by women in ideal health that had not earlier had breast cancer, but were thought to be in the higher risk bracket for developing the disease.

A major part of the data scrutinized during the study was derived from 8 large-scale clinical trials.

Popularity: 2% [?]